<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Tay-Sachs Disease - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Tay-Sachs Disease</span>
        </nav>

        <header class="page-header">
            <h1>Tay-Sachs Disease</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Genetic</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0010100" target="_blank">
                        MONDO:0010100
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Lysosomal Storage Disorder</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Neurodegenerative Disease</span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
        </div>

        <!-- Classifications -->
        

        <!-- Subtypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Infantile Tay-Sachs</div>
                
                <div class="item-desc">Classic form with onset at 3-6 months, rapidly progressive, fatal by age 4-5.</div>
                
                
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Juvenile Tay-Sachs</div>
                
                <div class="item-desc">Onset in childhood, slower progression, death in adolescence.</div>
                
                
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Late-Onset Tay-Sachs</div>
                
                <div class="item-desc">Adult onset, variable progression, compatible with longer survival.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Hexosaminidase A Deficiency</div>
                
                <div class="item-desc">Mutations in the HEXA gene cause deficient beta-hexosaminidase A enzyme. This enzyme is essential for degrading GM2 ganglioside in lysosomes. Without it, GM2 accumulates in neurons causing progressive neurodegeneration.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Ganglioside Catabolism
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006689" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19820796" target="_blank">PMID:19820796</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Tay-Sachs disease is an autosomal recessive disorder of sphingolipid metabolism, caused by enzyme hexosaminidase A deficiency that leads to an accumulation of GM2 in neurocytes which results in progressive loss of neurological function."</div>
                
                
                <div class="evidence-explanation">Case report confirms hexosaminidase A deficiency causes GM2 accumulation and neurodegeneration.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Neuronal GM2 Accumulation</div>
                
                <div class="item-desc">Progressive accumulation of GM2 ganglioside in neuronal lysosomes causes cell swelling, dysfunction, and death. Particularly affects neurons in the central nervous system leading to neurodegeneration.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Neurodegeneration
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0070997" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22025593" target="_blank">PMID:22025593</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal Œ≤-hexosaminidase and result in ganglioside accumulation in the brain."</div>
                
                
                <div class="evidence-explanation">Natural history study confirms GM2 ganglioside accumulation in the brain as the central pathophysiological mechanism.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29618308" target="_blank">PMID:29618308</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Inherited as a classical autosomal recessive disorder, this global disease of the nervous system induces developmental arrest with regression of attained milestones; neurodegeneration progresses rapidly to cause premature death in young children."</div>
                
                
                <div class="evidence-explanation">Review confirms neurodegeneration as the primary consequence of GM2 accumulation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Developmental Regression
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002376" target="_blank">
                            HP:0002376
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Loss of previously acquired milestones, typically starting at 3-6 months</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25143775" target="_blank">PMID:25143775</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"All of them had a developmental disorder as a chief complaint. 38%of patients had a history of developmental delay or regression"</div>
                
                
                <div class="evidence-explanation">Case series confirms developmental regression as a key presenting feature in GM2 gangliosidosis patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22025593" target="_blank">PMID:22025593</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."</div>
                
                
                <div class="evidence-explanation">Natural history study of 97 patients confirms developmental arrest in 83% of infantile GM2 gangliosidosis cases.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29618308" target="_blank">PMID:29618308</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Inherited as a classical autosomal recessive disorder, this global disease of the nervous system induces developmental arrest with regression of attained milestones; neurodegeneration progresses rapidly to cause premature death in young children."</div>
                
                
                <div class="evidence-explanation">Review describes developmental arrest with regression of milestones as a core feature of Tay-Sachs disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Cherry-Red Spot
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Ophthalmologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0010729" target="_blank">
                            HP:0010729
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Pathognomonic finding on fundoscopy</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19820796" target="_blank">PMID:19820796</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The accumulation of lipid in retinal ganglion cells that leads to a chalk-white appearance of the fundus called &#39;cherry red spot&#39; is the hallmark of Tay-Sachs disease."</div>
                
                
                <div class="evidence-explanation">Case report describes cherry-red spot as the hallmark ophthalmologic finding in Tay-Sachs disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Exaggerated Startle Response
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002267" target="_blank">
                            HP:0002267
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Hyperacusis with exaggerated startle to sound</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22025593" target="_blank">PMID:22025593</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."</div>
                
                
                <div class="evidence-explanation">Natural history study of 97 patients confirms exaggerated startle response (startling) in 65% of infantile GM2 gangliosidosis patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24534057" target="_blank">PMID:24534057</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The augmented startle reflex appeared between the age of 3 and 17 months and disappeared between the age of 4 and 6 years."</div>
                
                
                <div class="evidence-explanation">Electrophysiological study documents the temporal evolution of the augmented startle reflex in Tay-Sachs disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hypotonia
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001252" target="_blank">
                            HP:0001252
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Progresses to spasticity</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22025593" target="_blank">PMID:22025593</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."</div>
                
                
                <div class="evidence-explanation">Natural history study confirms hypotonia in 60% of infantile GM2 gangliosidosis patients at disease onset.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Seizures
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001250" target="_blank">
                            HP:0001250
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25143775" target="_blank">PMID:25143775</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"38%of patients had a history of developmental delay or regression and 22% had seizures."</div>
                
                
                <div class="evidence-explanation">Case series documents seizures as a clinical manifestation in GM2 gangliosidosis patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Macrocephaly
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0000256" target="_blank">
                            HP:0000256
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Due to brain swelling from ganglioside accumulation</div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Blindness
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Ophthalmologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0000618" target="_blank">
                            HP:0000618
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Progressive visual loss</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24011710" target="_blank">PMID:24011710</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Disorders such as Tay-Sachs or Niemann-Pick disease are the most familiar examples of dysfunction in sphingolipid metabolism and are typically associated with neurodegeneration and ocular findings such as blindness."</div>
                
                
                <div class="evidence-explanation">Review establishes blindness as a characteristic ocular finding in sphingolipidoses including Tay-Sachs disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HEXA
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Supportive Care
                    
                </div>
                
                <div class="item-desc">Symptomatic management including seizure control, nutrition support, respiratory care.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27491214" target="_blank">PMID:27491214</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Both are devastating diseases without cure or specific treatment however, with the use of supportive aggressive medical management, the lifespan and quality of life has been extended for both diseases."</div>
                
                
                <div class="evidence-explanation">Review confirms supportive care extends lifespan and quality of life in GM2 gangliosidoses including Tay-Sachs disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic Counseling
                    
                </div>
                
                <div class="item-desc">Carrier screening especially in high-risk populations.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12108829" target="_blank">PMID:12108829</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Carrier testing for Tay-Sachs disease should be offered to couples when at least one individual is of Ashkenazi Jewish (carrier frequency 1/30), Pennsylvania Dutch, Southern Louisiana Cajun, or Eastern Quebec French Canadian descent."</div>
                
                
                <div class="evidence-explanation">Review establishes carrier screening recommendations for high-risk populations including Ashkenazi Jews.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Substrate Reduction Therapy
                    
                </div>
                
                <div class="item-desc">Investigational approaches to reduce GM2 synthesis.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27491214" target="_blank">PMID:27491214</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Treatment with FDA-approved glucose analogs to reduce the amount of ganglioside substrate is used as off-label treatments for some patients."</div>
                
                
                <div class="evidence-explanation">Review confirms substrate reduction therapy using glucose analogs is being used off-label in GM2 gangliosidoses.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Gene Therapy
                    
                </div>
                
                <div class="item-desc">Experimental AAV-based gene therapy in clinical trials.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35145305" target="_blank">PMID:35145305</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy."</div>
                
                
                <div class="evidence-explanation">First-in-human AAV gene therapy trial demonstrates safety and proof-of-concept for Tay-Sachs disease treatment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Hexosaminidase A Activity
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Decreased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Absent or severely reduced in leukocytes or fibroblasts</div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    GM2 Ganglioside
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Accumulates in brain tissue</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Tay-Sachs Disease
category: Genetic
parents:
- Lysosomal Storage Disorder
- Neurodegenerative Disease
disease_term:
  preferred_term: Tay-Sachs disease
  term:
    id: MONDO:0010100
    label: Tay-Sachs disease
has_subtypes:
- name: Infantile Tay-Sachs
  description: Classic form with onset at 3-6 months, rapidly progressive, fatal by age 4-5.
- name: Juvenile Tay-Sachs
  description: Onset in childhood, slower progression, death in adolescence.
- name: Late-Onset Tay-Sachs
  description: Adult onset, variable progression, compatible with longer survival.
pathophysiology:
- name: Hexosaminidase A Deficiency
  description: &gt;
    Mutations in the HEXA gene cause deficient beta-hexosaminidase A enzyme.
    This enzyme is essential for degrading GM2 ganglioside in lysosomes.
    Without it, GM2 accumulates in neurons causing progressive neurodegeneration.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Ganglioside Catabolism
    term:
      id: GO:0006689
      label: ganglioside catabolic process
  evidence:
  - reference: PMID:19820796
    supports: SUPPORT
    snippet: &#34;Tay-Sachs disease is an autosomal recessive disorder of sphingolipid metabolism, caused by enzyme hexosaminidase A deficiency that leads to an accumulation of GM2 in neurocytes which results in progressive loss of neurological function.&#34;
    explanation: Case report confirms hexosaminidase A deficiency causes GM2 accumulation and neurodegeneration.
- name: Neuronal GM2 Accumulation
  description: &gt;
    Progressive accumulation of GM2 ganglioside in neuronal lysosomes causes
    cell swelling, dysfunction, and death. Particularly affects neurons in
    the central nervous system leading to neurodegeneration.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Neurodegeneration
    term:
      id: GO:0070997
      label: neuron death
  evidence:
  - reference: PMID:22025593
    supports: SUPPORT
    snippet: &#34;G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal Œ≤-hexosaminidase and result in ganglioside accumulation in the brain.&#34;
    explanation: Natural history study confirms GM2 ganglioside accumulation in the brain as the central pathophysiological mechanism.
  - reference: PMID:29618308
    supports: SUPPORT
    snippet: &#34;Inherited as a classical autosomal recessive disorder, this global disease of the nervous system induces developmental arrest with regression of attained milestones; neurodegeneration progresses rapidly to cause premature death in young children.&#34;
    explanation: Review confirms neurodegeneration as the primary consequence of GM2 accumulation.
phenotypes:
- name: Developmental Regression
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Loss of previously acquired milestones, typically starting at 3-6 months
  phenotype_term:
    preferred_term: Developmental Regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: PMID:25143775
    supports: SUPPORT
    snippet: &#34;All of them had a developmental disorder as a chief complaint. 38%of patients had a history of developmental delay or regression&#34;
    explanation: Case series confirms developmental regression as a key presenting feature in GM2 gangliosidosis patients.
  - reference: PMID:22025593
    supports: SUPPORT
    snippet: &#34;Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%).&#34;
    explanation: Natural history study of 97 patients confirms developmental arrest in 83% of infantile GM2 gangliosidosis cases.
  - reference: PMID:29618308
    supports: SUPPORT
    snippet: &#34;Inherited as a classical autosomal recessive disorder, this global disease of the nervous system induces developmental arrest with regression of attained milestones; neurodegeneration progresses rapidly to cause premature death in young children.&#34;
    explanation: Review describes developmental arrest with regression of milestones as a core feature of Tay-Sachs disease.
- name: Cherry-Red Spot
  category: Ophthalmologic
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Pathognomonic finding on fundoscopy
  phenotype_term:
    preferred_term: Cherry-Red Spot
    term:
      id: HP:0010729
      label: Cherry red spot of the macula
  evidence:
  - reference: PMID:19820796
    supports: SUPPORT
    snippet: &#34;The accumulation of lipid in retinal ganglion cells that leads to a chalk-white appearance of the fundus called &#39;cherry red spot&#39; is the hallmark of Tay-Sachs disease.&#34;
    explanation: Case report describes cherry-red spot as the hallmark ophthalmologic finding in Tay-Sachs disease.
- name: Exaggerated Startle Response
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Hyperacusis with exaggerated startle to sound
  phenotype_term:
    preferred_term: Exaggerated Startle Response
    term:
      id: HP:0002267
      label: Exaggerated startle response
  evidence:
  - reference: PMID:22025593
    supports: SUPPORT
    snippet: &#34;Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%).&#34;
    explanation: Natural history study of 97 patients confirms exaggerated startle response (startling) in 65% of infantile GM2 gangliosidosis patients.
  - reference: PMID:24534057
    supports: SUPPORT
    snippet: &#34;The augmented startle reflex appeared between the age of 3 and 17 months and disappeared between the age of 4 and 6 years.&#34;
    explanation: Electrophysiological study documents the temporal evolution of the augmented startle reflex in Tay-Sachs disease.
- name: Hypotonia
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Progresses to spasticity
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:22025593
    supports: SUPPORT
    snippet: &#34;Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%).&#34;
    explanation: Natural history study confirms hypotonia in 60% of infantile GM2 gangliosidosis patients at disease onset.
- name: Seizures
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:25143775
    supports: SUPPORT
    snippet: &#34;38%of patients had a history of developmental delay or regression and 22% had seizures.&#34;
    explanation: Case series documents seizures as a clinical manifestation in GM2 gangliosidosis patients.
- name: Macrocephaly
  category: Neurological
  frequency: FREQUENT
  notes: Due to brain swelling from ganglioside accumulation
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
- name: Blindness
  category: Ophthalmologic
  frequency: VERY_FREQUENT
  notes: Progressive visual loss
  phenotype_term:
    preferred_term: Blindness
    term:
      id: HP:0000618
      label: Blindness
  evidence:
  - reference: PMID:24011710
    supports: SUPPORT
    snippet: &#34;Disorders such as Tay-Sachs or Niemann-Pick disease are the most familiar examples of dysfunction in sphingolipid metabolism and are typically associated with neurodegeneration and ocular findings such as blindness.&#34;
    explanation: Review establishes blindness as a characteristic ocular finding in sphingolipidoses including Tay-Sachs disease.
biochemical:
- name: Hexosaminidase A Activity
  presence: Decreased
  context: Absent or severely reduced in leukocytes or fibroblasts
- name: GM2 Ganglioside
  presence: Elevated
  context: Accumulates in brain tissue
genetic:
- name: HEXA
  association: Causative
  notes: Autosomal recessive, higher frequency in Ashkenazi Jewish population
treatments:
- name: Supportive Care
  description: Symptomatic management including seizure control, nutrition support, respiratory care.
  evidence:
  - reference: PMID:27491214
    supports: SUPPORT
    snippet: &#34;Both are devastating diseases without cure or specific treatment however, with the use of supportive aggressive medical management, the lifespan and quality of life has been extended for both diseases.&#34;
    explanation: Review confirms supportive care extends lifespan and quality of life in GM2 gangliosidoses including Tay-Sachs disease.
- name: Genetic Counseling
  description: Carrier screening especially in high-risk populations.
  evidence:
  - reference: PMID:12108829
    supports: SUPPORT
    snippet: &#34;Carrier testing for Tay-Sachs disease should be offered to couples when at least one individual is of Ashkenazi Jewish (carrier frequency 1/30), Pennsylvania Dutch, Southern Louisiana Cajun, or Eastern Quebec French Canadian descent.&#34;
    explanation: Review establishes carrier screening recommendations for high-risk populations including Ashkenazi Jews.
- name: Substrate Reduction Therapy
  description: Investigational approaches to reduce GM2 synthesis.
  evidence:
  - reference: PMID:27491214
    supports: SUPPORT
    snippet: &#34;Treatment with FDA-approved glucose analogs to reduce the amount of ganglioside substrate is used as off-label treatments for some patients.&#34;
    explanation: Review confirms substrate reduction therapy using glucose analogs is being used off-label in GM2 gangliosidoses.
- name: Gene Therapy
  description: Experimental AAV-based gene therapy in clinical trials.
  evidence:
  - reference: PMID:35145305
    supports: SUPPORT
    snippet: &#34;This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy.&#34;
    explanation: First-in-human AAV gene therapy trial demonstrates safety and proof-of-concept for Tay-Sachs disease treatment.
datasets:
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Tay-Sachs_Disease.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>